about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Back to the draw­ing board for triple-neg­a­tive breast can­cer tar­gets, re­searchers pro­pose new com­bo ap­proach

6 years ago
Discovery

Is HKEX ready to re­turn to biotech busi­ness? In­no­Care tests wa­ters with hopes to fetch $257M in IPO

6 years ago
Financing
China

Af­ter hit­ting big in mul­ti­ple myelo­ma, J&J, Gen­mab now have a new 'break­through' in NSCLC to boast about

6 years ago
FDA+

J&J's fa­vorite CAR-T de­vel­op­er, cur­rent­ly owned by a Chi­nese CRO, is lay­ing the ground­work for US IPO

6 years ago
Financing
Cell/Gene Tx

Ver­sant woos Mor­phoSys' ex-CSO to its boom­ing dis­cov­ery en­gine, with big plans for new star­tups

6 years ago
People
Financing

Chi­nese biotech bags $50M+ for I/O, au­toim­mune work, start­ing with ALK5 in­hibitor

6 years ago
Financing
China

Neil Wood­ford in the game to buy back his for­mer un­list­ed port­fo­lio that's prov­ing hard to sell — re­ports

6 years ago
Financing
Deals

Mit­subishi joins Ei­sai, 3SBio's bet on mul­ti­spe­cif­ic an­ti­bod­ies, up­ping Num­ab's Se­ries B haul to $23M+

6 years ago
Financing

Ahead of cru­cial PhII read­out, Sh­iono­gi lines up an op­tion to buy out biotech part­ner and its non-amy­loid Alzheimer's ...

6 years ago
Deals

Dana-Far­ber, MD An­der­son, MIT im­pose trav­el re­stric­tions amid broad­er ef­forts to con­tain coro­n­avirus dam­age in US

6 years ago
Coronavirus

More than half of its gross sales ul­ti­mate­ly went to pay­ers as re­bates, Sanofi says

6 years ago
Pharma

GSK's Em­ma Walm­s­ley award­ed £8.4M pay pack­age af­ter £2.5M rise, fi­nal­ly catch­ing up with fel­low phar­ma CEOs

6 years ago
People

'Dra­mat­ic times': How did an $8B surge in NIH grants over five years change re­search on the ground (if at all)?

6 years ago
Discovery
In Focus

Can re­for­mu­la­tion of an As­traZeneca castoff ri­val Takeda's new heart­burn drug? Here's a $26M bet on yes

6 years ago
Financing

AM­AG CMO hits the ex­it just as biotech search­es for new CEO to right a ship rocked by Mak­e­na con­tro­ver­sy

6 years ago
People
Pharma

New study sug­gests it costs $1.3B in R&D in­vest­ment to bring a drug to mar­ket. How did it get there?

6 years ago
R&D

Boast­ing new dis­cov­er­ies from Xtan­di, Er­lea­da in­ven­tors, ORIC pitch­es $86M IPO on can­cer drugs tar­get­ed at re­sis­tance

6 years ago
R&D

With one ri­val down, No­var­tis-part­nered biotech scores $100M round to fund mid-stage tri­als of fi­bro­sis drug

6 years ago
Financing

'Un­heard-of speed­s': Trump, new­ly warmed up to bio­phar­ma, prais­es in­dus­try's coro­n­avirus re­sponse at White House ...

6 years ago
Coronavirus

Mer­ck clears PFS end­point in con­fir­ma­to­ry tri­al for Keytru­da in clas­si­cal Hodgkin lym­phoma

6 years ago
R&D

As US di­als up coro­n­avirus re­sponse, BIO taps Vir's George Scan­gos to head com­mit­tee co­or­di­nat­ing in­dus­try ef­forts

6 years ago
People
Coronavirus

Ex ni­hi­lo: Take­da leads $100M+ round to fund biotech's sneak at­tack on tu­mors, pro­pelling new IL-2, CT­LA-4 drugs to ...

6 years ago
Financing
Startups

Turn­ing fo­cus to clin­i­cal work, Ve­rastem ax­es 31 jobs, scales back can­cer drug pro­mo­tion af­ter dis­ap­point­ing sales

6 years ago
People
R&D

Jim Wilson's gene ther­a­py start­up Pas­sage Bio bucks mar­ket sen­ti­ments, rais­ing up­sized $216M IPO

6 years ago
Financing
Startups
First page Previous page 79808182838485 Next page Last page
A service from the Financial Times